Shamir R. Mehta, MD, MSc; Jia Wang, MSc; David A. Wood, MD; et al.
free access
JAMA Cardiol. 2022;7(11):1091-1099. doi:10.1001/jamacardio.2022.3032
This secondary analysis of a randomized clinical trial determines whether complete revascularization improves angina status in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel coronary artery disease.
Ki Hong Choi, MD; Yong Hwan Park, MD; Young Bin Song, MD, PhD; et al.
free access
JAMA Cardiol. 2022;7(11):1100-1108. doi:10.1001/jamacardio.2022.3203
This 3-year follow-up of a randomized clinical trial assesses the long-term safety and efficacy of P2Y12 inhibitor monotherapy following 3 months of dual antiplatelet therapy after percutaneous coronary intervention.
Sanjit S. Jolly, MD, MSc; Sulaiman AlRashidi, MD; Marc-André d鈥橢ntremont, MD, MPH; et al.
free access
JAMA Cardiol. 2022;7(11):1110-1118. doi:10.1001/jamacardio.2022.3399
This randomized clinical trial determines whether routinely using ultrasonography guidance for femoral arterial access for coronary angiography/intervention reduces bleeding or vascular complications.
Danielle S. Burstein, MD; Joseph W. Rossano, MD, MS; JoAnn Lindenfeld, MD; et al.
free access
JAMA Cardiol. 2022;7(11):1121-1127. doi:10.1001/jamacardio.2022.3070
This study compares use and outcomes of graft from donors with US Public Health Services risk criteria vs those with standard risk in children vs adults in a contemporary cohort.
So Mi Jemma Cho, PhD; Satoshi Koyama, MD, PhD; Yunfeng Ruan, PhD; et al.
free access
JAMA Cardiol. 2022;7(11):1129-1137. doi:10.1001/jamacardio.2022.3191
This cohort study investigates if genetic predisposition to hypertension is associated with cardiovascular disease risk beyond measured blood pressure.
Byron C. Jaeger, PhD; Adam P. Bress, PharmD, MS; Joshua D. Bundy, PhD; et al.
free access
has audio
JAMA Cardiol. 2022;7(11):1138-1146. doi:10.1001/jamacardio.2022.3345
This secondary analysis of the Systolic Blood Pressure Intervention Trial evaluates the long-term effects of randomization to intensive treatment with the incidence of cardiovascular and all-cause mortality approximately 4.5 years after the trial ended.
-
Podcast:
Longer-Term All-Cause and Cardiovascular Mortality With Intensive Blood Pressure Control
-
Invited Commentary
Blood Pressure Control After SPRINT鈥擝ack to Reality
Daniel W. Jones, MD; Donald Clark III, MD; Michael E. Hall, MD
JAMA Cardiol
-
Podcast:
Longer-Term All-Cause and Cardiovascular Mortality With Intensive Blood Pressure Control
João Pedro Ferreira, MD, PhD; Faiez Zannad, MD, PhD; Javed Butler, MD, MPH; et al.
open access
JAMA Cardiol. 2022;7(11):1148-1159. doi:10.1001/jamacardio.2022.2924
This post hoc analysis of a randomized clinical trial of patients with heart failure evaluates the association of empagliflozin with albuminuria levels in study participants.
Matthew D. Solomon, MD, PhD; Thomas Leong, MPH; Sue Hee Sung, MPH; et al.
free access
JAMA Cardiol. 2022;7(11):1160-1169. doi:10.1001/jamacardio.2022.3305
This cohort study assesses the association between ascending thoracic aorta aneurysm size and patient outcomes.